# Zydus Lifesciences: how the business works

> For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Zydus Lifesciences Limited · NSE: ZYDUSLIFE · BSE: 532321 · Sector: Healthcare

Updated for Q2 FY27 · checked 12 Nov 2026

This is the plain-text version of https://cityfort.in/stocks/zydus-lifesciences. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Zydus Lifesciences: how the business works", with the page URL.

## In short

Wholesalers, distributors and hospitals in the US, India and other countries pay Zydus for its medicines and health products; most of the money goes on materials, staff and running costs such as research, and ₹18.4 of every ₹100 was left as profit in FY26.

- In FY26 buyers in the US paid 43.2% of Zydus's revenue and buyers in India 35.8%; one customer, not named, paid 12.4%.
- Of every ₹100 that came in during FY26, ₹26.4 went on materials, ₹16.0 on staff and ₹25.2 on other running costs, after currency gains.

## Key facts

**What does Zydus Lifesciences do?**

Zydus Lifesciences, based in Ahmedabad, makes generic medicines for the US, branded medicines prescribed by doctors in India and medicines for other countries. It also sells consumer health products through Zydus Wellness and orthopaedic implants through Amplitude Surgical of France. [S1, S14]

**How does Zydus Lifesciences make money?**

Zydus Lifesciences earns most of its money selling medicines. Of its ₹26,720 crore of product sales in FY26, North America formulations were ₹11,682 crore, India formulations ₹6,574 crore, consumer wellness ₹3,913 crore and international markets ₹3,070 crore. [S14]

**Who pays Zydus Lifesciences?**

In FY26 buyers in the US paid 43.2% of Zydus Lifesciences' ₹27,148 crore revenue, buyers in India 35.8%, Europe 9.9% and other countries 11.2%. One customer, not named, paid 12.4% of FY26 revenue. [S1]

**How big is Zydus Lifesciences?**

Zydus Lifesciences reported FY26 revenue of ₹27,148 crore and profit to shareholders of ₹5,095 crore (as restated in its Q2 FY27 results). It has 44 manufacturing facilities and about 30,000 employees. [S6, S1]

**Who owns Zydus Lifesciences?**

On 30 Sep 2026 the promoter group owned 75.01% of Zydus Lifesciences, Indian institutions 11.28%, foreign investors 7.05% and others 6.66%. The FY25 annual report shows most promoter shares held by Pankaj R. Patel as trustee of the Zydus Family Trust. [S37, S2]

**How much debt does Zydus Lifesciences have?**

On 30 Sep 2026 Zydus Lifesciences had borrowings of ₹13,250 crore and cash and liquid investments of ₹5,216 crore, a net debt of ₹8,034 crore (Cityfort calculation). On 31 Mar 2025 it had ₹4,643 crore more cash than debt. [S6, S1]

**What has Zydus Lifesciences bought since 2025?**

Zydus Lifesciences bought French orthopaedic-implant maker Amplitude Surgical for a total cost of €300 million (Jul–Oct 2025) and US company Assertio for about US$166.4 million (Jun 2026). Its subsidiary Zydus Wellness bought Comfort Click of the UK for £239 million in Aug 2025. [S45, S46, S6, S52]

**How did Zydus Lifesciences do in Q2 FY27?**

In Q2 FY27 (Jul–Sep 2026) Zydus Lifesciences' revenue rose 29.2% from a year earlier to ₹7,910 crore, while profit to shareholders fell 26.6% to ₹926 crore. [S6, S12]

**What is Zydus Lifesciences' credit rating?**

CRISIL rated Zydus Lifesciences' long-term bank facilities AAA with a Stable outlook and its short-term debt A1+, reaffirmed in letters dated 10 Sep 2026. [S38]

## What does Zydus Lifesciences sell?

Zydus makes medicines. In the US it mostly sells generics: cheaper copies of medicines whose patents have ended. In India it sells its own brands, which doctors prescribe. It also owns most of Zydus Wellness, a consumer health company, and since Jul 2025 a French maker of hip and knee implants.

- **North America formulations:** Generic and specialty medicines sold in the US and Canada. ₹11,682 crore of sales in FY26, 43.7% of product sales. Since Jun 2026 this includes Assertio's cancer-care biologic Rolvedon. [S14, S6]
- **India formulations:** Branded medicines prescribed by doctors in India. ₹6,574 crore in FY26. Medicines for long-term (chronic and sub-chronic) conditions were 56.9% of the portfolio in the 12 months to Sep 2026 (AWACS). [S14, S12]
- **Consumer wellness:** Zydus Wellness brands such as Glucon-D, Complan, Sugar Free, Nycil and Everyuth, plus UK online brands of Comfort Click from Aug 2025. ₹3,913 crore in FY26. [S14, S1, S6]
- **International markets formulations:** Medicines sold in other countries through subsidiaries and distributors. ₹3,070 crore in FY26. [S14, S1]
- **MedTech:** Knee and hip implants from Amplitude Surgical, France, part of Zydus since 29 Jul 2025. ₹782 crore in FY26. [S14, S45]
- **APIs and alliances:** Active pharmaceutical ingredients (the chemicals inside medicines) sold to other drug makers, plus partner income. ₹698 crore in FY26. [S14, S1]

## Who pays Zydus Lifesciences?

- **Buyers in the US (43.2% of revenue):** Generic and specialty medicines. One US-based wholesaler owed more than 10% of Zydus's trade receivables on 31 Mar 2026. Share is of FY26 revenue by customer location. [S1]
- **Buyers in India (35.8% of revenue):** Branded medicines reach patients through a distributor network and chemists, and hospitals buy directly. India also buys Zydus Wellness consumer products. [S1]
- **Buyers in Europe (9.9% of revenue):** Rose from ₹402 crore in FY25 to ₹2,675 crore in FY26, the first year with Amplitude (France) and Comfort Click (UK) in the accounts. [S1, S6]
- **Buyers in other countries (11.2% of revenue):** Medicines sold in other markets through subsidiaries and distributors. [S1]
- **Customer concentration:** largest customer 12.4% of revenue. One customer, not named, paid ₹3,364 crore, 12.4% of FY26 revenue (Cityfort calculation from the segment note). A single customer also passed 10% in FY23 (13.3%) and FY24 (11.2%), but not in FY22 or FY25. [S1, S2, S3, S4]

## Where the money went (FY26)

1. In FY26 Zydus took in ₹27,148 crore from sales plus ₹510 crore of other income.
2. Materials and goods bought cost ₹7,293 crore, ₹26.4 of every ₹100 that came in.
3. Staff cost ₹4,418 crore. Other running costs were ₹6,963 crore after ₹1,280 crore of currency gains (₹4.6 per ₹100) counted against them.
4. One-off charges took ₹517 crore (₹1.9 per ₹100), ₹398 crore of it the Astellas patent settlement.
5. After depreciation, interest, tax and the share of minority owners, ₹5,095 crore was left for Zydus shareholders.

Sources: S6.

## Key numbers by year (₹ crore)

Financials: consolidated, ₹ crore. Financial year runs April to March (March year end). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (₹ per share) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY22 | 15,110 | 3,500 | 23.2% | 4,487 | 29.7% | 43.83 | 2,105 | 1,203 | 902 | S4, S5 |
| FY23 | 17,237 | 3,350 | 19.4% | 1,960 | 11.4% | 19.3 | 2,689 | 1,031 | 1,658 | S3 |
| FY24 | 19,547 | 5,489 | 28.1% | 3,860 | 19.7% | 38.14 | 3,196 | 907 | 2,290 | S2 |
| FY25 | 23,242 | 6,897 | 29.7% | 4,526 | 19.5% | 44.97 | 6,781 | 1,694 | 5,087 | S1 |
| FY26 (restated) | 27,148 | 8,056 | 29.7% | 5,095 | 18.8% | 50.63 | 2,117 | 2,672 | −555 | S6, S1 |

- EBITDA = profit before interest, tax and wear-and-tear of assets.
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of 30 Sep 2026, ₹ crore)

On 30 Sep 2026 Zydus's borrowings were ₹8,034 crore more than its cash and liquid investments; on 31 Mar 2025 its cash had been ₹4,643 crore more than its debt. [S6, S1, S12, S21]

| Item | Value |
| --- | --- |
| Total debt | 13,250 |
| Cash and investments | 5,216 |
| Net debt (debt minus cash) | 8,034 |
| Net worth (shareholders' money) | 27,817 |
| Debt to equity (times) | 0.48 |

- Borrowings exclude lease liabilities (rent owed under leases) of ₹717 crore.
- Cash and liquid investments = cash ₹669 crore + other bank balances ₹883 crore + current investments ₹3,664 crore. Non-current investments of ₹3,452 crore are not counted. Net debt is a Cityfort calculation.
- Zydus's own measure, on a definition it does not disclose: net debt 0.19 times equity and 0.62 times EBITDA on 30 Sep 2026. Dr Sharvil Patel said on 4 Nov 2026 that net debt fell from ₹5,900 crore to ₹5,200 crore in the quarter.
- Net debt (Cityfort calculation) was ₹4,577 crore on 31 Mar 2026. In FY26 Zydus took ₹7,071 crore of new long-term borrowings and spent ₹6,602 crore on acquisitions.
- Goodwill and other intangible assets were ₹15,822 crore on 30 Sep 2026, against ₹7,092 crore on 31 Mar 2025 (Cityfort calculation: sum of the two lines).
- Net worth is the equity belonging to Zydus shareholders. Minority owners, mainly of Zydus Wellness, held another ₹2,506 crore.

## Who owns Zydus Lifesciences? (shareholding, Q2 FY27)

| Holder | % of shares |
| --- | --- |
| Promoters | 75.01% |
| Promoter shares pledged (% of promoter shares) | 0.0% |
| Foreign institutions (FII) | 7.05% |
| Indian institutions (DII) | 11.28% |
| Public | 6.66% |

Sources: S37, S36, S35, S34, S33, S32, S31, S30, S29, S28, S27, S26, S25.

## What could go wrong

### US generic prices and competition

US buyers paid 43.2% of FY26 revenue. CRISIL's Dec 2024 report notes price erosion in US generics. When giving the FY27 margin outlook on 19 May 2026, Dr Sharvil Patel cited competition for lenalidomide and mirabegron and saroglitazar launch costs. [S1, S39, S23, S12]

What to watch: North America formulation sales each quarter: ₹3,315 crore in Q2 FY27.

### USFDA plant inspections

The Baddi plant received a USFDA warning letter on 3 Jun 2026. The Jarod injectables plant received one in Aug 2024, which the FY26 annual report says was resolved. US sales depend on plants passing these inspections. [S51, S41, S1, S12]

What to watch: Baddi remediation, and follow-up on the SEZ-II and Moraiya inspections, which closed with 1 and 5 observations.

### Debt after acquisitions

Net debt (Cityfort calculation) went from net cash of ₹4,643 crore on 31 Mar 2025 to ₹8,034 crore on 30 Sep 2026. The company put net debt at 0.62 times EBITDA on its own measure on 30 Sep 2026. CRISIL reaffirmed AAA/Stable on 10 Sep 2026. [S6, S1, S12, S38, S21]

What to watch: Net debt to EBITDA. Dr Sharvil Patel said on 4 Nov 2026 that Zydus is comfortable up to one times.

### Loss-making medical devices business

The medical technologies segment lost ₹113 crore in FY26 (restated) and ₹150 crore in H1 FY27, before one-off items and tax. Goodwill and other intangible assets rose from ₹7,092 crore on 31 Mar 2025 to ₹15,822 crore on 30 Sep 2026. [S6, S1]

What to watch: The medical technologies segment result each quarter.

### Weaker cash from operations in FY26

Cash from operations fell from ₹6,781 crore in FY25 to ₹2,117 crore in FY26, with a ₹2,624 crore working-capital outflow and a ₹1,753 crore currency adjustment on consolidation. Free cash flow was −₹555 crore. [S1, S6]

What to watch: FY27 cash from operations. Inventories were ₹6,882 crore on 30 Sep 2026, up from ₹5,628 crore on 31 Mar 2026.

### US lawsuits and settlements

In US generic-drug pricing antitrust cases, plaintiffs alleged that many drug makers, including Zydus's US subsidiary, engaged in anti-competitive behaviour; it agreed on 5 Sep 2026 to pay US$5.9 million to indirect reseller plaintiffs, without any admission of fault or wrongdoing. In Feb 2026 Zydus agreed to pay Astellas US$120 million to end mirabegron patent litigation. [S53, S6, S48]

What to watch: New settlements or provisions in the results notes.

### One large customer

One customer, not named, paid ₹3,364 crore, 12.4% of FY26 revenue. One US-based wholesaler owed more than 10% of trade receivables on 31 Mar 2026. [S1]

What to watch: The large-customer line in the FY27 segment note.

## What to watch

Next: Q3 FY27 results, Date not announced yet.

- **US FDA date for saroglitazar:** The US FDA set 27 Nov 2026 as its target action date for Zydus's saroglitazar application in PBC, a liver disease (announced 27 May 2026). Dr Sharvil Patel said on 4 Nov 2026 that FY28 would bring no meaningful revenue from it.
- **Plant inspections:** Progress on the Baddi warning letter of 3 Jun 2026, and on the 1 and 5 USFDA observations at the SEZ-II and Moraiya plants.
- **Debt and margins:** Net debt was 0.62 times EBITDA on 30 Sep 2026 on the company's own measure. Dr Sharvil Patel said on 19 May and 4 Nov 2026 that Zydus expects an FY27 EBITDA margin above 24%; H1 FY27 was 24.0% on the company's measure.

## Sources

- S1: Integrated Annual Report 2025-26 (FY26). Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/14/2/2025-2026.pdf (published 30 Jun 2026)
- S2: Annual Report 2024-25 (FY25). Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/14/2/2024-2025.pdf (published 3 Jul 2025)
- S3: Annual Report 2023-24 (FY24). Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/14/2/2023-2024_1.pdf (published 12 Jul 2024)
- S4: Annual Report 2022-23 (FY23). Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/14/2/2022-2023.pdf (published 18 May 2023)
- S5: Annual Report 2021-22 (FY22). Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/public/pdf/financial/annual/Annual-Report%202021-2022.pdf (published 15 Jul 2022)
- S6: Q2 FY27 results (standalone and consolidated, with notes and balance sheet). Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/14/3/Q2-04-Nov-2026.pdf (published 4 Nov 2026)
- S7: Q1 FY27 results. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/14/3/Q1-11-Aug-2026.pdf (published 11 Aug 2026)
- S8: Q4 FY26 and FY26 audited results. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/14/3/Q4-19-May-2026.pdf (published 19 May 2026)
- S9: Q3 FY26 results. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/14/3/Q3-09-Feb-2026.pdf (published 9 Feb 2026)
- S10: Q2 FY26 results. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/14/3/Q2-06-Nov-2025.pdf (published 6 Nov 2025)
- S11: Q1 FY26 results. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/14/3/Q1-12-Aug-2025.pdf (published 12 Aug 2025)
- S12: Press release: financial performance for Q2 and H1 FY27. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/21/83/Zydus-Lifesciences-Financial-Performance-for-Q2-and-H1-FY27.pdf (published 4 Nov 2026)
- S13: Press release: financial performance for Q1 FY27. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/21/83/Zydus-Lifesciences-Limited-financial-performance-for-Q1-FY27.pdf (published 11 Aug 2026)
- S14: Press release: financial performance for Q4 and full year FY26. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/21/83/Zydus-Lifesciences-Financial-Performance-for-Q4---Full-Year-FY-26.pdf (published 19 May 2026)
- S15: Press release: financial performance for Q3 and 9M FY26. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/21/83/Zydus-Lifesciences-Limited-Financial-Performance-for-Q-3---9M-FY26.pdf (published 9 Feb 2026)
- S16: Press release: financial performance for Q2 and H1 FY26. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/21/83/Zydus-Lifesciences-Limited-Financial-Performance-for-Q2---H1-FY26.pdf (published 6 Nov 2025)
- S17: Press release: financial performance for Q1 FY26. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/21/83/Zydus-Lifesciences-Limited-Financial-Performance-for-Q1-FY26.pdf (published 12 Aug 2025)
- S18: Press release: Q4 FY25 and full year FY25 results. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/21/83/Zydus-Lifesciences-Q4FY25-result.pdf (published 20 May 2025)
- S19: Press release: financial performance for Q4 and full year FY24. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/21/83/Zydus-Lifesciences-Limited-Financial-Performance-for-Q4---Full-Year-FY24.pdf (published 17 May 2024)
- S20: Press release: financial performance for Q4 and full year FY23. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/21/83/Press-Release-18-05-2023.pdf (published 18 May 2023)
- S21: Q2 FY27 earnings call transcript (call 4 Nov 2026). Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/16/0/Earnings-call-transcript-04-Nov-26.pdf (published 7 Nov 2026)
- S22: Q1 FY27 earnings call transcript (call 11 Aug 2026). Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/16/0/Earnings-call-transcript-11-Aug-26.pdf (published 18 Aug 2026)
- S23: Q4 FY26 earnings call transcript (call 19 May 2026). Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/16/0/Earnings-call-transcript-19-May-26.pdf (published 24 May 2026)
- S24: Q3 FY26 earnings call transcript (call 10 Feb 2026). Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/16/0/Earnings-Call-transcript-10-Feb-2026.pdf (published 15 Feb 2026)
- S25: Shareholding pattern as of 31 Dec 2023. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/19/0/31-Dec-23.pdf (published 8 Jan 2024)
- S26: Shareholding pattern as of 31 Mar 2024. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/19/0/31-Mar-24.pdf (published 9 Apr 2024)
- S27: Shareholding pattern as of 30 Jun 2024. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/19/0/30-Jun-24.pdf (published 11 Jul 2024)
- S28: Shareholding pattern as of 30 Sep 2024. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/19/0/30-Sep-24.pdf (published 9 Oct 2024)
- S29: Shareholding pattern as of 31 Dec 2024. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/19/0/31-Dec-24.pdf (published 20 Jan 2025)
- S30: Shareholding pattern as of 31 Mar 2025. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/19/0/31-Mar-25.pdf (published 12 Apr 2025)
- S31: Shareholding pattern as of 30 Jun 2025. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/19/0/30-Jun-252025_07_18_07_27_02.pdf (published 18 Jul 2025)
- S32: Shareholding pattern as of 30 Sep 2025. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/19/0/30-Sep-25.pdf (published 14 Oct 2025)
- S33: Shareholding pattern as of 31 Dec 2025 (revised). Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/19/0/31-Dec-25_Revised.pdf (published 27 May 2026)
- S34: Shareholding pattern as of 31 Mar 2026. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/19/0/31-Mar-26.pdf (published 9 Apr 2026)
- S35: Shareholding pattern as of 18 Jun 2026 (post-buyback, Reg 31(1)(c)). Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/19/0/18-Jun-26.pdf (published 24 Jun 2026)
- S36: Shareholding pattern as of 30 Jun 2026. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/19/0/30-Jun-26.pdf (published 11 Jul 2026)
- S37: Shareholding pattern as of 30 Sep 2026. Zydus Lifesciences Ltd (company IR site). https://www.zyduslife.com/investor/admin/uploads/19/0/30-Sep-26.pdf (published 7 Oct 2026)
- S38: Intimation of credit rating: CRISIL letters dated 10 Sep 2026 (AAA/Stable, A1+ reaffirmed); rationale attached as scanned images. Zydus Lifesciences Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/Cadilahc_11092026143115_SEIntimationcreditrating11092026.pdf (published 11 Sep 2026)
- S39: CRISIL Ratings rating rationale, Zydus Lifesciences Ltd, 27 Dec 2024. CRISIL Ratings Ltd. https://www.crisil.com/mnt/winshare/Ratings/RatingList/RatingDocs/ZydusLifesciencesLimited_December%2027_%202024_RR_360135.html (published 27 Dec 2024)
- S40: NSE security-wise bhavcopy (sec_bhavdata_full), 11 Nov 2026: ZYDUSLIFE EQ close Rs 1,199.50. NSE (nsearchives.nseindia.com). https://nsearchives.nseindia.com/products/content/sec_bhavdata_full_11112026.csv (published 11 Nov 2026)
- S41: Clarification on receipt of USFDA warning letter for the Jarod injectables facility (intimation of 30 Aug 2024). Zydus Lifesciences Ltd (exchange disclosure, company IR site). https://www.zyduslife.com/investor/admin/uploads/21/82/Clarification-w-r-t--intimation-dated-August-30--2024--regarding-receipt-of-warning-letter-from-USFDA-03-Sep-2024.pdf (published 3 Sep 2024)
- S42: Acquisition of the API business of Sterling Biotech Ltd (business transfer agreement). Zydus Lifesciences Ltd (exchange disclosure, company IR site). https://www.zyduslife.com/investor/admin/uploads/21/82/Acquisition-of-API-Business-17-Sep-2024.pdf (published 17 Sep 2024)
- S43: Exclusive negotiations to acquire 85.6% of Amplitude Surgical SA, France. Zydus Lifesciences Ltd (exchange disclosure, company IR site). https://www.zyduslife.com/investor/admin/uploads/21/82/Intimation-of-acquisition-of-shares-of-Amplitude-Surgical-SA--France-11-03-2025.pdf (published 11 Mar 2025)
- S44: Closure of USFDA inspection at the oncology injectable plant, Ahmedabad (2 observations). Zydus Lifesciences Ltd (exchange disclosure, company IR site). https://www.zyduslife.com/investor/admin/uploads/21/83/Closure-of-USFDA-inspection-at-Zydus--oncology-injectable-plant-at-Ahmedabad.pdf (published 18 Jun 2025)
- S45: Completion of block acquisition of 85.6% of Amplitude Surgical. Zydus Lifesciences Ltd (exchange disclosure, company IR site). https://www.zyduslife.com/investor/admin/uploads/21/82/Completion-of-Block-Acquisition-of-Amplitude-Surgical-29-Jul-2025.pdf (published 29 Jul 2025)
- S46: Update on acquisition of Amplitude shares (tender offer and squeeze-out). Zydus Lifesciences Ltd (exchange disclosure, company IR site). https://www.zyduslife.com/investor/admin/uploads/21/82/Update-on-Acquisition-of-Shares-of-Amplitude-26-Oct-2025.pdf (published 26 Oct 2025)
- S47: Closing of acquisition of Agenus biologics manufacturing facilities (US). Zydus Lifesciences Ltd (exchange disclosure, company IR site). https://www.zyduslife.com/investor/admin/uploads/21/82/Agenus-Transaction-Closing-15-Jan-2026.pdf (published 15 Jan 2026)
- S48: Settlement agreement with Astellas on Myrbetriq (mirabegron). Zydus Lifesciences Ltd (exchange disclosure, company IR site). https://www.zyduslife.com/investor/admin/uploads/21/82/Update-on-litigation-12-Feb-2026.pdf (published 12 Feb 2026)
- S49: Agreement to acquire Assertio Holdings Inc.. Zydus Lifesciences Ltd (exchange disclosure, company IR site). https://www.zyduslife.com/investor/admin/uploads/21/82/Acquisition-of-Assertio-13-May-2026.pdf (published 13 May 2026)
- S50: Update: US FDA Priority Review for saroglitazar NDA in PBC, PDUFA date 27 Nov 2026. Zydus Lifesciences Ltd (exchange disclosure, company IR site). https://www.zyduslife.com/investor/admin/uploads/21/82/Update-27-May-2026.pdf (published 27 May 2026)
- S51: Receipt of USFDA warning letter for the Baddi formulations facility. Zydus Lifesciences Ltd (exchange disclosure, company IR site). https://www.zyduslife.com/investor/admin/uploads/21/82/Update-03-Jun-2026.pdf (published 3 Jun 2026)
- S52: Completion of acquisition and merger of Assertio Holdings Inc.. Zydus Lifesciences Ltd (exchange disclosure, company IR site). https://www.zyduslife.com/investor/admin/uploads/21/82/Completion-of-merger-of-Assertio-Holdings-Inc----16-06-2026.pdf (published 16 Jun 2026)
- S53: Settlement with indirect reseller plaintiffs, US generic drug pricing antitrust litigation (US$5.9 mn). Zydus Lifesciences Ltd (exchange disclosure, company IR site). https://www.zyduslife.com/investor/admin/uploads/21/82/Settlement-Agreement-05-Sep-2026.pdf (published 5 Sep 2026)
- S54: Completion of acquisition of the API business of Sterling Biotech Ltd. Zydus Lifesciences Ltd (exchange disclosure, company IR site). https://www.zyduslife.com/investor/admin/uploads/21/82/Update-on-Acquisition-of-API-Business-02-Nov-2026.pdf (published 2 Nov 2026)
- S55: Appointment of Walker Chandiok & Co LLP as statutory auditors (rotation, from the 32nd AGM). Zydus Lifesciences Ltd (exchange disclosure, company IR site). https://www.zyduslife.com/investor/admin/uploads/21/82/Appointment-of-Statutory-Auditors---04-11-2026.pdf (published 4 Nov 2026)
- S56: Change in CFO: Nitin Parekh to Tushar Shroff (from 1 Sep 2025). Zydus Lifesciences Ltd (exchange disclosure, company IR site). https://www.zyduslife.com/investor/admin/uploads/21/82/Change-in-CFO-(KMP)---20-05-2025.pdf (published 20 May 2025)
- S57: Press release: Sun Pharma reports Q4FY26 and FY26 results (peer filing). Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE). https://sunpharma.com/wp-content/uploads/2026/05/Press-Release-Sun-Pharma-Q4FY26-Financial-Result.pdf (published 22 May 2026)
- S58: Press release: Q4 FY26 and FY26 results (peer filing). Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/CIPLA_13052026125750_SignedPressrelease13052026Signed.pdf (published 13 May 2026)
- S59: Q4 FY26 results filing: press release (IFRS) and Ind AS results with notes (peer filing). Dr. Reddy's Laboratories Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/DRREDDY_12052026163727_SEintimation_Outcome_of_BM_12052026_signed.pdf (published 12 May 2026)
